Natera sues ArcherDX for oncology patent infringement
DNA testing developer Natera is suing ArcherDX, a molecular technology company, for allegedly infringing a patent related to multiplex polymerase chain reaction (PCR) technology.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
27 March 2019 Stanford University has accused genetic testing company Natera of infringing two patents that cover a non-invasive method of testing if transplanted organs are being rejected.
14 May 2020 Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
13 May 2021 Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
27 March 2019 Stanford University has accused genetic testing company Natera of infringing two patents that cover a non-invasive method of testing if transplanted organs are being rejected.
14 May 2020 Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
13 May 2021 Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
27 March 2019 Stanford University has accused genetic testing company Natera of infringing two patents that cover a non-invasive method of testing if transplanted organs are being rejected.
14 May 2020 Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
13 May 2021 Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
